Equities

Tanvex BioPharma Inc

Tanvex BioPharma Inc

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TWD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3817862,226
Total Receivables, Net102.760.36
Total Inventory10817190
Prepaid expenses1058486
Other current assets, total------
Total current assets6041,0442,402
Property, plant & equipment, net1,9282,1512,114
Goodwill, net------
Intangibles, net3.381210
Long term investments201204180
Note receivable - long term------
Other long term assets269.907.53
Total assets2,7633,4204,714
LIABILITIES
Accounts payable------
Accrued expenses144116137
Notes payable/short-term debt000
Current portion long-term debt/capital leases16312589
Other current liabilities, total576322
Total current liabilities364303249
Total long term debt1,5681,7151,670
Total debt1,7321,8391,759
Deferred income tax------
Minority interest------
Other liabilities, total1010--
Total liabilities1,9422,0281,919
SHAREHOLDERS EQUITY
Common stock1,3403,5273,525
Additional paid-in capital12,43111,06110,988
Retained earnings (accumulated deficit)(12755)(12969)(11327)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(194)(227)(390)
Total equity8211,3912,795
Total liabilities & shareholders' equity2,7633,4204,714
Total common shares outstanding136122122
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.